AzTrials
AzTrials

Heart FailureAISEARHFNCT07021599

Artificial Intelligence Versus Sonographer Echocardiogram Analysis and Reporting in Patients With Heart Failure

A study testing Tailored AI echocardiogram analysis and reporting system in people with Heart Failure, run by Prince of Wales Hospital, Shatin, Hong Kong at 1 site in Hong Kong.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This is a non-inferiority, three-year, multicenter, double-blinded randomized controlled study of an AI versus experienced sonographer echocardiogram analysis in HF patients. Consecutive patients presented for echocardiogram examination with new or worsening HF symptom and positive HF blood markers will be recruited. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Heart Failure
What is being tested?
Tailored AI echocardiogram analysis and reporting system
Could I receive a placebo?
No, everyone receives an active treatment
How many people
514 participants
Where
1 siteHong Kong
Study dates
1 Jul 2025to 3 Dec 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Aged 18 years or above
  • Has new or worsening of heart failure symptoms
  • Elevated heart failure blood markers (N-terminal prohormone of brain natriuretic peptide, "NTproBNP") within 3 months from enrolment or by point-of-care blood test, to ensure that the patient's symptoms are cardiac origin
  • Provision of written informed consent

Who cannot join

  • Known severe valvular heart disease
  • Prior prosthetic valve implantation
  • Previously known or suspected >=severe tricuspid regurgitation, >=moderate aortic regurgitation, >=moderate mitral stenosis or pericardial disease during detected during image acquisition
  • Insufficient image quality for proper analysis determined by the scanning sonographer (estimated to be 15% of all echocardiograms screened)

Trial locations and contacts

1 site in 1 country.

Hong Kong1 site
  • Prince of Wales Hospital

    Hong Kong, Shatin, 0000

Other trials in Hong Kong

About this study

Official title: Artificial Intelligence Versus Sonographer Echocardiogram Analysis and Reporting in Patients With Heart Failure: A Randomized Controlled Trial

This is a non-inferiority, three-year, multicenter, double-blinded randomized controlled study of an AI versus experienced sonographer echocardiogram analysis in HF patients. Consecutive patients presented for echocardiogram examination with new or worsening HF symptom and positive HF blood markers will be recruited. A target of 514 patients will be randomized 1:1 to receive either AI or sonographer echocardiogram analysis. The primary endpoint of diagnostic accuracy is the complete agreement of disease grading with an experienced cardiologist (American Society of Echocardiography level III) using a standardized grading chart. Important secondary endpoints include the time used for echocardiogram report drafting and report endorsement, 6-month heart failure symptom and hospitalization, and the cost-effectiveness of AI to increase echocardiogram service. Clinical, biochemical and echocardiographic predictors of worsening of heart failure and hospitalization will be identified.

Read the detailed description

Background Unmet Need for Streamlined Echocardiogram Algorithm Heart failure (HF) is a global pandemic affecting more than 64 million people in the world.

In Hong Kong, the prevalence of HF is estimated to be 2-3% with a steep rise of new onset HF hospitalization in the older age group. The estimated annual worldwide economic burden of HF was 108 billion United States dollars, with direct costs to healthcare systems accounted for 60% and indirect costs to society driven by premature mortality, morbidity and lost productivity accounted for the remaining 40%. Timely diagnosis of HF etiology with early appropriate treatment are critical to reduce HF hospitalization and mortality. While HF with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) requires different guideline directed medical therapy (GDMT), HF patients with severe valvular heart disease requires interventional treatment. Echocardiogram (cardiac ultrasound) is the key diagnosticmodality to phenotype HF and to guide subsequent appropriate treatment. Access to echocardiogram in Asia Pacific is severely limited (e.g. average waiting time in Hong Kong for routine echocardiogram is 12-18 months), which results in delay in appropriate treatment and hence poor outcomes. While image acquisition is easier to teach, analysis in echocardiogram is time consuming and requires years of training to become proficient, and yet has significant inter-observer variability. Therefore, there is a shortage of fully trained sonographers globally. A streamlined echocardiogram analysis pathway that can enhance the efficiency while improving the diagnostic accuracy of HF etiology is appealing.

Emerging role of Artificial Intelligence in Echocardiogram Artificial intelligence (AI) has emerged as a useful tool with the potential to enhance cardiovascular care including in disease diagnosis, treatment guidance and outcome prediction. Collaborator of this study, David Ouyang et al., has developed machine learning algorithm for fully automated assessment of left ventricular ejection function (LVEF), aortic valve stenosis (AS) and mitral valve regurgitation (MR), with similar accuracy compared to manual analysis by experienced sonographers with reference to cardiologists ("gold standard"). Similar works has also been done by other teams. However, most of these validation studies are conducted based on retrospective echocardiogram cohort. Besides, there can be bias when a different sonographer than the scanning sonographer interprets the images, and that potentially compromised the real-life diagnostic accuracy of sonographers.

Local Heart Failure Data and Application Artificial Intelligence in Echocardiogram Studies from our team has demonstrated that early diagnosis and intensified HF GDMT can reduce HF hospitalization from 13.1% to 8.6% (Hazard ratio = 0.65, p<0.01). Besides, a strong association of 30-day unplanned HF hospitalization with severe valvular heart disease, mostly AS or MR, was found (Odd ratio =72.04, p=0.03). This implies that early phenotyping the mechanism of HF is important. From our unpublished pilot data of patients presented with HF symptom, echocardiogram image acquisition took only 54.2% of the total echocardiogram process time while the remaining were used for analysis by sonographer. When compared, AI used a significantly shorter time for echocardiogram analysis (324 seconds vs 1057 seconds, p<0.01), with a 91.6% agreement rate on LVEF grading and severity of AS and MR. However, this pilot data was collected retrospectively, and the sample size was small. Therefore, it remains unclear whether AI is as accurate and more efficient than experienced sonographers in analyzing multiple possible echocardiogram abnormalities that can interact with each other for HF patients. Moreover, whether the addition of AI analysis will affect the final grading by cardiologists has not been studied.

In this research project proposal, Investigator aim to assess whether a tailored AI echocardiogram analysis and reporting system is as accurate as an experienced sonographer in HF patients by conducting a multicenter double-blinded randomized controlled study.

Conditions
Heart Failure
Being tested
Tailored AI echocardiogram analysis and reporting system
Keywords
Echocardiogram, Artificial Intelligence, Alogrithm, Echocardiological image analysis
Medical subject headings
Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tailored AI echocardiogram analysis and reporting systemDiagnostic test

    In the AI analysis and reporting pathway, sonographers only need to acquire the echocardiogram images, then the AI algorithm will complete the analysis and report drafting for final endorsement by experienced cardiologists. To ensure blinding of group assignment to the endorsing experienced cardiologists, measurement format and reporting phrases and interface used by AI and sonographers will be standardized.

Study groups in NCT07021599
Study groupRoleWhat they receive
Tailored AI echocardiogram analysis and reporting systemExperimentalAn experienced cardiologist will be provided with AI's measurements, draft disease grading and report for review. The experienced cardiologist will provide a final grading of left ventricular function, AS and MR on the standardized grading chart, and endorse the final echocardiogram report.
Receives: Diagnostic Test: Tailored AI echocardiogram analysis and reporting system
Echocardiologist interpretation and analysis of Echo imagesActive comparatorAn experienced cardiologist (with American Society of Echocardiography level III capacity), will be provided with sonographer's measurements, draft disease grading and report for review.
Receives: Diagnostic Test: Tailored AI echocardiogram analysis and reporting system

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of complete agreement in LVEF assessments

    To assess the rate of agreement in LVEF assessments between AI and sonographers with final adjudication by experienced cardiologist

    Measured: 6 month

  2. Rate of complete agreement in assessments of AS severity

    To assess the rate of agreement in severity of AS assessments between AI and sonographers with final adjudication by experienced cardiologist

    Measured: 6 month

  3. Rate of complete agreement in assessment of MR severity

    To assess the rate of agreement in severity of MR assessments between AI and sonographers with final adjudication by experienced cardiologist

    Measured: 6 month

Secondary outcomes (23)
  1. Time used for image acquisition echocardiogram process

    Compare the time used by AI system and sonographers for image acquisition.

    Measured: 6 month

  2. Time used forreport drafting echocardiogram process

    Compare the time used by AI system and sonographers for report drafting.

    Measured: 6 month

  3. Time used for report endorsement

    Compare the time used by AI system and sonographers for report endorsement.

    Measured: 6 month

  4. Time used for total echocardiogram process

    Compare the time used by AI system and sonographers for total echocardiogram process.

    Measured: 6 month

  5. NYHA classification

    Compare of NYHA classification of subjects at 6 month and baseline between 2 intervention groups

    Measured: 6 month

  6. Symptom burden

    Compare of symptom burden of subjects at 6 month and baseline between 2 intervention groups

    Measured: 6 month

  7. NTproBNP level

    Compare of NTproBNP level of subjects at 6 month and baseline between 2 intervention groups

    Measured: 6 month

  8. Rate of heart failure hospitalisation

    Compare of Rate of heart failure hospitalisation of subjects at 6 month and baseline between 2 intervention groups

    Measured: 6 month

  9. Rate of all-cause mortality

    Compare of Rate of all-cause mortality of subjects at 6 month and baseline between 2 intervention groups

    Measured: 6 month

  10. Dosage of GDMT

    Compare GDMT dosage change of Heart Failure subjects at 6 month and baseline between 2 intervention groups

    Measured: 6 month

  11. Rate of valvular intervention

    Compare Rate of valvular intervention in subjects with severe valvular heart disease at 6 month and baseline between 2 intervention groups

    Measured: 6 month

  12. Rate of LVEF assessment change made by cardiologist on AI generated reports

    Rate of LVEF assessment change made by cardiologist on AI generated reports

    Measured: 6 month

  13. Rate of change in severity of AS made by cardiologist on AI generated reports

    Rate of change in severity of AS made by cardiologist on AI generated reports

    Measured: 6 month

  14. Rate of change in severity of MR made by cardiologist on AI generated reports

    Rate of change in severity of MR made by cardiologist on AI generated reports

    Measured: 6 month

  15. Subgroup analysis of LVEF agreement rate in low complexity disease

    To assess the rate of agreement in LVEF assessments between AI and sonographers with final adjudication by experienced cardiologist in low complexity disease

    Measured: 6 month

  16. Subgroup analysis of LVEF agreement rate in intermediate complexity disease

    To assess the rate of agreement in LVEF assessments between AI and sonographers with final adjudication by experienced cardiologist in intermediate complexity disease

    Measured: 6 month

  17. Subgroup analysis of LVEF agreement rate in high complexity disease

    To assess the rate of agreement in LVEF assessments between AI and sonographers with final adjudication by experienced cardiologist in high complexity disease

    Measured: 6 month

  18. Subgroup analysis of severity of AS agreement rate in low complexity disease

    To assess the rate of agreement in severity of AS between AI and sonographers with final adjudication by experienced cardiologist in low complexity disease

    Measured: 6 month

  19. Subgroup analysis of severity of AS agreement rate in intermediate complexity disease

    To assess the rate of agreement in severity of AS between AI and sonographers with final adjudication by experienced cardiologist in intermediate complexity disease

    Measured: 6 month

  20. Subgroup analysis of severity of AS agreement rate in high complexity disease

    To assess the rate of agreement in severity of AS between AI and sonographers with final adjudication by experienced cardiologist in high complexity disease

    Measured: 6 month

  21. Subgroup analysis of severity of MR agreement rate in low complexity disease

    To assess the rate of agreement in severity of MR between AI and sonographers with final adjudication by experienced cardiologist in low complexity disease

    Measured: 6 month

  22. Subgroup analysis of severity of MR agreement rate in intermediate complexity disease

    To assess the rate of agreement in severity of MR between AI and sonographers with final adjudication by experienced cardiologist in intermediate complexity disease

    Measured: 6 month

  23. Subgroup analysis of severity of MR agreement rate in high complexity disease

    To assess the rate of agreement in severity of MR between AI and sonographers with final adjudication by experienced cardiologist in high complexity disease

    Measured: 6 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jun 2025
  2. Study start1 Jul 2025
  3. Primary completion3 Jul 2028 (estimated)
  4. Study completion3 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
514 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07021599
Sponsor's protocol ID
2024.587
Acronym
AISEARHF
Status last verified
Sep 2026
First submitted
5 Jun 2025
Last updated
16 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Tailored AI echocardiogram analysis and reporting system in people with Heart Failure, run by Prince of Wales Hospital, Shatin, Hong Kong at 1 site in Hong Kong.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of complete agreement in LVEF assessments (time frame: 6 month). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in